Evidence map›Paper›PMID 42470600›Full record

SynthesisAdvances in therapy2026

Efficacy and Safety of Statins in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis.

Han Deng, Ran Wang, Yuhang Yin, Rui Zhang, Xiangbo Xu, Xiaohui Fang, Xingshun Qi

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Han Deng *Department of Drug Clinical Trial, Yuebei People's Hospital Affiliated to Shantou University Medical College, Shaoguan, China.
Ran Wang *Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110840, China.
Yuhang Yin *Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110840, China.
Rui Zhang *Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110840, China.
Xiangbo XuDepartment of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Xiaohui FangDepartment of Gastroenterology, Huainan Chaoyang Hospital, Huainan, China.
Xingshun QiLiver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110840, China. xingshunqi@126.com.ORCID http://orcid.org/0000-0002-9448-6739

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLiver cirrhosis is a global health burden with high morbidity and mortality. Recent evidence suggests the benefits of statins in liver cirrhosis due to its pleiotropic effects. This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of statins in patients with liver cirrhosis.

methodsPubMed, EMBASE, and Cochrane Library databases were systematically searched to identify all relevant randomized controlled trials (RCTs) regarding use of statins in cirrhosis. Risk ratios (RRs) or mean differences (MDs) with their 95% confidence intervals (CIs) were pooled for the outcomes, including overall mortality, hepatic venous pressure gradient (HVPG), cirrhosis-related complications, and adverse events. Heterogeneity was calculated. Trial sequential analysis (TSA) was performed.

resultsThirteen RCTs were included. Statins significantly decreased the overall mortality (RR 0.63, 95% CI 0.47-0.84, I

conclusionsStatins may reduce the overall mortality and HVPG in patients with liver cirrhosis. Additionally, statins can prevent from spontaneous bacterial peritonitis, but not other cirrhosis-related complications. CLINICAL REGISTRATION: The protocol was prospectively registered on the PROSPERO database (CRD420251000903).

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsLiver CirrhosisHumansRandomized Controlled Trials as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsCirrhosisComplicationHVPGMortalityStatins

Identifiers

PMID42470600
PMCPMC13619750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.